Pharmacoeconomic analysis of treatment with Bretaris Genuair for chronic obstructive pulmonary disease

The aim of this study was to determine the optimal therapy of chronic obstructive pulmonary disease (COPD) according to costeffectiveness of Bretaris Genuair, Spiriva Respimat, Spiriva Handihaler or Seebri Breezhaler.

Methods. Pharmacoeconomic evaluation was performed using cost effectiveness analysis, economic impact analysis, and cost analysis. Initially, search of pharmacoeconomic data for treatment with Bretaris Genuair, Spiriva Respimat, Spiriva Handihaler or Seebri Breezhaler was performed using specialized databases Pubmed and Medlink. Then, two clinical situations were modelled. The first situation included a direct comparison between Bretaris Genuair and Spiriva Handihaler. The second situation included comparison between all the studied drugs.

Results. The first clinical situation presumed that all patients treated with Spiriva Handihaler were switched to Bretaris Genuair. This allows saving 695,785 RUB per 100 patients. Therapy with Bretaris Genuair was characterized by the min imal cost per a clinical effectiveness unit, which was lung function improvement, in comparison with Spiriva Respimat, Spiriva Handihaler and Seebri Breezhaler. The second situation presumed that proportion of patients treated with Spiriva Respimat, Spiriva Handihaler and Seebri Breezhaler was equally about 33%. In this situation, switching at least of 10% of patients from each drug to treatment with Bretaris Genuair could save 50,000 to 68,000 RUB.

Conclusion. Therapy of COPD using Bretaris Genuair is superior over the treatment with Spiriva Handihaler, Spiriva Respimat and Seebri Breezhaler in terms of pharmacoeconomic evaluation.

1. Brief guidelines for ambulatory management of chronic obstructive pulmonary disease (GOLD, update 2015). Translated from English (ed. by A.S.Belevskiy). Moscow:

2. RRO; 2015 (in Russian).

3. WHO. Chronic Obstructive Pulmonary Disease (COPD). Available at: http://www.who.int/respiratory/copd/ru (in Russian).

4. Krysanov I.S. Cost analysis of chronic obstructive pulmonary disease in Russian Federation. Kachestvennaya klinicheskaya praktika. 2014; 2: 51–56 (in Russian).

5. Kulikov A.Yu. Komarov I.A. Pharmacoeconomic study of Mcholinolytic agents (Spiriva) in chronic obstructive pulmonary disease. Farmakoekonomika. 2012; 5 (3): 20–26 (in Russian).

6. Zhuravkov Yu.L., Koroleva A.A., Zakharenko, A.G. Management of acute exacerbation of chronic obstructive pulmonary disease. Voennaya meditsina. 2015; 2: 110–114 (in Russian).

7. Boueri F.M., BucherBartelson B.L., Glenn K.A. et al. Quality of life measured with a generic instrument (Short Form36) improves following pulmonary rehabilitation in patients with COPD. Chest. 2001; 119 (1); 77–84.

8. Chikina S.Yu., Avdeev S.N. New bronchodilator glycopy rronium bromide: a review of clinical trials. Atmosfera. 2013; 4: 40–46 (in Russian).

9. Karabis A., Lindner L., Mocarski M. et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: A systematic review and network metaanalysis. Int. J. COPD. 2013; 8: 405–423.

10. Beier J., Kirsten A.M., Mruz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderatetosevere chronic obstructive pulmonary disease: Results from a 6week, randomized, controlled phase IIIb study. COPD. 2013; 10 (4): 511–522.

11. State Register of marginal cost pricing. Available at: http://grls.rosminzdrav.ru/pricelims.aspx (in Russian).

12. An Order of Ministry of Health and Social Development of the Russian Federation «About confirmation of standard medical care for patients with chronic obstructive pulmonary disease», N271, Nov. 23, 2004. Available at: www.consultant.ru (in Russian).

13. An Order of Ministry of Health and Social Development of the Russian Federation «About confirmation of standard primary medical care for patients with acute exacerbation of chronic obstructive pulmonary disease», N1214н, Dec. 20, 2012. Available at: http://garant.ru (in Russian).

14. An Order of Ministry of Health and Social Development of the Russian Federation «About confirmation of standard tertiary medical care for patients with chronic obstructive pulmonary disease», N327, May 11, 2007. Available at: www.consultant.ru (in Russian).

15. Established tariff on healthcare service payment according to Territorial Programme of Mandatory Healthcare Insurance in Moscow, 2015. Available at: http://www.mgfoms.ru/medicinskie*organizacii/tarifi (in Russian).

16. Statistical proceedings of Healthcare Ministry of Russia. Morbidity of Russian population in 2013. Moscow; 2014 (in Russian).